干旱区生态环境知识资源中心(Arid): OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.

Arid

DOI	10.1200/JCO.2016.34.15_suppl.TPS7583
	OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.
	Le Gouill, Steven; Davies, Andrew; Bouabdallah, Kamal; Chiron, David; Rule, Simon
来源期刊	JOURNAL OF CLINICAL ONCOLOGY
ISSN	0732-183X
EISSN	1527-7755
出版年	2016
卷号	34 期号:15
类型	Meeting Abstract
语种	英语
国家	France ; England
收录类别	SCI-E ; CPCI-S
WOS记录号	WOS:000404711505095
WOS类目	Oncology
WOS研究方向	Oncology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/194303
作者单位	(1)Univ Hosp Nantes, Nantes, France;(2)Southampton Gen Hosp, Southampton, Hants, England;(3)CHU Haut Leveque, Dept Haematol, Bordeaux, France;(4)INSERM UMR 892 Nantes, Nantes, France;(5)Univ Plymouth, Plymouth, Devon, England
推荐引用方式 GB/T 7714	Le Gouill, Steven,Davies, Andrew,Bouabdallah, Kamal,et al. OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.[J],2016,34(15).
APA	Le Gouill, Steven,Davies, Andrew,Bouabdallah, Kamal,Chiron, David,&Rule, Simon.(2016).OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma..JOURNAL OF CLINICAL ONCOLOGY,34(15).
MLA	Le Gouill, Steven,et al."OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.".JOURNAL OF CLINICAL ONCOLOGY 34.15(2016).